16/01/2012

German review panel sees added benefit for J&J hepatitis C drug

German review panel ruling a key factor in setting the price of new drugs in the German system.

Germany’s IQWiG drug-review panel found that Johnson & Johnson’s hepatitis C treatment telaprevir showed evidence of an added benefit when used together with older treatments, according to a statement posted on the panel’s website today.

Germany’s Federal Joint Committee will use IQWiG’s recommendation to make a final ruling on whether telaprevir, also known by the brand name Incivo, helps patients more than existing therapies do, a key factor in setting the price of new drugs in the German system.

By Naomi Kresge

Businessweek

http://www.businessweek.com/

http://www.businessweek.com/news/2012-01-16/german-review-panel-sees-added-benefit-for-j-j-hepatitis-c-drug.html

Share this page

More...

DISCLAIMER

The EATG is not responsible for the content of this article. It does not necessarily reflect EATG views or opinions.

FAIR USE NOTICE

The information above may contain copyrighted material which has not always been specifically authorised by the copyright owner. Such material is made available for educational purposes to advance the understanding of scientific, ethical, legal and social issues. It is believed that this constitutes a 'fair use' of any such copyrighted material. This material is distributed without profit via the subscription to the daily digest.